146 related articles for article (PubMed ID: 38054958)
21. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).
Wielenberg CF; Fostitsch JC; Volz C; Marks R; Michalski K; Wäsch R; Zeiser R; Ruf J; Meyer PT; Klein C
Nuklearmedizin; 2024 Apr; ():. PubMed ID: 38593856
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma.
Bailly C; Carlier T; Tessoulin B; Gastinne T; Kraeber-Bodere F; Le Gouill S; Bodet-Milin C
Hematol Oncol; 2022 Oct; 40(4):796-800. PubMed ID: 35044695
[No Abstract] [Full Text] [Related]
24. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
Yu L; Zou R; He J; Qu C
Crit Rev Oncol Hematol; 2024 Jul; 199():104390. PubMed ID: 38782146
[TBL] [Abstract][Full Text] [Related]
25. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
26. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT.
Li S; Wang H; Wang G; Lu X; Yang J
Clin Nucl Med; 2023 May; 48(5):445-447. PubMed ID: 36716490
[TBL] [Abstract][Full Text] [Related]
28. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
29. Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy.
Linguanti F; Abenavoli EM; Berti V; Lopci E
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230629
[TBL] [Abstract][Full Text] [Related]
30. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.
Ferrari C; Maggialetti N; Masi T; Nappi AG; Santo G; Niccoli Asabella A; Rubini G
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33803667
[TBL] [Abstract][Full Text] [Related]
31. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.
Vercellino L; de Jong D; di Blasi R; Kanoun S; Reshef R; Schwartz LH; Dercle L
Front Oncol; 2021; 11():664688. PubMed ID: 34123825
[TBL] [Abstract][Full Text] [Related]
32. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
34. Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma.
Mulholland N; Chandra J; Sanderson R; Kuhnl A
Radiology; 2023 Jun; 307(5):e221362. PubMed ID: 37310248
[TBL] [Abstract][Full Text] [Related]
35. Baseline [
Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
37. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.
Cohen D; Beyar-Katz O; Even-Sapir E; Perry C
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2447-2449. PubMed ID: 35146579
[No Abstract] [Full Text] [Related]
38. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
39. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
40. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
